Der Gastroenterologe

, Volume 4, Issue 2, pp 115–123 | Cite as

Primär sklerosierende Cholangitis

Surveillance und Malignität
Schwerpunkt
First Online:
  • 131 Downloads

Zusammenfassung

Die primär sklerosierende Cholangitis (PSC) ist mit einem erhöhten Risiko gastrointestinaler Malignome assoziiert. Patienten mit PSC und Colitis ulcerosa haben ein noch höheres Risiko für die Entwicklung kolorektaler Karzinome als Patienten mit Colitis ulcerosa alleine. Die Überwachung mit jährlichen Kontrollkoloskopien mit Stufenbiopsieentnahme ist hier gut etabliert. Das erhöhte Risiko von cholangiozelluläen Karzinomen hingegen stellt eine komplexe Herausforderung für den behandelnden Gastroenterologen dar. Nur ein umfassendes Vorgehen mit Labordiagnostik, Bildgebung und komplexer umfangreicher endoskopischer Diagnostik erlaubt die rechtzeitige Diagnose von cholangiozellulären Karzinomen. Dies ist für die Prognose des Patienten und zur Bestimmung des Zeitpunkts einer Lebertransplantation, die die einzige kurative Therapie darstellt, von großer Relevanz. In dieser Übersichtsarbeit legen wir einen Schwerpunkt auf die mit der PSC assoziierten gastrointestinalen Malignome und diskutieren mögliche Überwachungsstrategien.

Schlüsselwörter

Primär sklerosierende Cholangitis Überwachungsstrategien Gallengangskarzinom Endoskopische retrograde Cholangiography Koloskopie 

Primary sclerosing cholangitis

Surveillance and malignancy

Abstract

Primary sclerosing cholangitis (PSC) is associated with an increased risk of gastrointestinal malignancies. Patients with PSC and ulcerative colitis have a higher risk of developing colorectal cancer than patients with ulcerative colitis alone. Surveillance employing annual screening colonoscopy is well established. However, the risk of cholangiocarcinoma remains a complex challenge for the gastroenterologist. Only comprehensive diagnostics including laboratory studies, imaging, and complex endoscopic diagnostics allow timely recognition of cholangiocarcinoma. This is most important for the prognosis of patients and relevant for determining the optimal time for liver transplantation, which remains the only curative treatment available so far. In this review, we focus on the gastrointestinal malignancies associated with PSC and discuss possible surveillance strategies.

Keywords

Primary sclerosing cholangitis Surveillance Cholangiocarcinoma Endoscopic retrograde cholangiography Colonoscopy 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der Autor Jochen Wedemeyer ist in der Vergangenheit als Referent für die Firma Falk tätig gewesen und hat Reisekostenerstattung der Firmen Boston Scientific, Olympus und Philips erhalten. Der Autor Tobias Weismüller hat in der Vergangenheit Reisekostenerstattung der Firmen Falk und GlaxoSmithKline erhalten.

Literatur

  1. 1.
    Boberg KM, Aadland E, Jahnsen J et al (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33: 99–103PubMedCrossRefGoogle Scholar
  2. 2.
    Card TR, Solaymani-Dodaran M, West J (2008) Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 48: 939–944PubMedCrossRefGoogle Scholar
  3. 3.
    Weismuller TJ, Wedemeyer J, Kubicka S et al (2008) The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48 (Suppl 1): 38–57CrossRefGoogle Scholar
  4. 4.
    Moff SL, Kamel IR, Eustace J et al (2006) Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 64: 219–223PubMedCrossRefGoogle Scholar
  5. 5.
    Berstad AE, Aabakken L, Smith HJ et al (2006) Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 4: 514–520PubMedCrossRefGoogle Scholar
  6. 6.
    Burak KW, Angulo P, Lindor KD (2003) Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 98: 1155–1158PubMedCrossRefGoogle Scholar
  7. 7.
    Bjornsson E, Olsson R, Bergquist A et al (2008) The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134: 975–980PubMedCrossRefGoogle Scholar
  8. 8.
    Gelbmann CM, Rummele P, Wimmer M et al (2007) Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 102: 1221–1229PubMedCrossRefGoogle Scholar
  9. 9.
    Nakanuma Y, Zen Y (2007) Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: The latest addition to the sclerosing cholangitis family. Hepatol Res 37 (Suppl 3): 478–486CrossRefGoogle Scholar
  10. 10.
    Tischendorf JJ, Hecker H, Kruger M et al (2007) Characterization, outcome and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 102: 107–114PubMedCrossRefGoogle Scholar
  11. 11.
    Broome U, Olsson R, Loof L et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615PubMedCrossRefGoogle Scholar
  12. 12.
    Stiehl A, Rudolph G, Kloters-Plachky P et al (2002) Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 36: 151–156PubMedCrossRefGoogle Scholar
  13. 13.
    Gluck M, Cantone NR, Brandabur JJ et al (2008) A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol 42: 1032–1039PubMedCrossRefGoogle Scholar
  14. 14.
    Kaya M, Petersen BT, Angulo P et al (2001) Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 96: 1059–1066PubMedCrossRefGoogle Scholar
  15. 15.
    Claessen MM, Vleggaar FP, Tytgat KM et al (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50: 158–164PubMedCrossRefGoogle Scholar
  16. 16.
    Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327PubMedCrossRefGoogle Scholar
  17. 17.
    Said K, Glaumann H, Bergquist A (2008) Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 48: 598–605PubMedGoogle Scholar
  18. 18.
    Buckles DC, Lindor KD, Larusso NF et al (2002) In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 97: 1138–1142PubMedCrossRefGoogle Scholar
  19. 19.
    Karlsen TH, Schrumpf E, Boberg KM (2008) Gallbladder polyps in primary sclerosing cholangitis: not so benign. Curr Opin Gastroenterol 24: 395–399PubMedCrossRefGoogle Scholar
  20. 20.
    Harnois DM, Gores GJ, Ludwig J et al (1997) Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 27: 512–516PubMedCrossRefGoogle Scholar
  21. 21.
    Brandsaeter B, Isoniemi H, Broome U et al (2004) Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 40: 815–822PubMedCrossRefGoogle Scholar
  22. 22.
    Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22: 1404–1408PubMedGoogle Scholar
  23. 23.
    Vera A, Gunson BK, Ussatoff V et al (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75: 1983–1988PubMedCrossRefGoogle Scholar
  24. 24.
    Kim WR, Therneau TM, Wiesner RH et al (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75: 688–694PubMedCrossRefGoogle Scholar
  25. 25.
    Dickson ER, Murtaugh PA, Wiesner RH et al (1992) Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103: 1893–1901PubMedGoogle Scholar
  26. 26.
    Bergquist A, Glaumann H, Persson B, Broome U (1998) Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311–316PubMedCrossRefGoogle Scholar
  27. 27.
    Tischendorf JJ, Meier PN, Strassburg CP et al (2006) Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 41: 1227–1234PubMedCrossRefGoogle Scholar
  28. 28.
    Bjornsson E, Kilander A, Olsson R (1999) CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19: 501–508PubMedCrossRefGoogle Scholar
  29. 29.
    Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW et al (1999) Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 31: 305–309PubMedCrossRefGoogle Scholar
  30. 30.
    Boberg KM, Jebsen P, Clausen OP et al (2003) Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation. J Hepatol 39: 453PubMedCrossRefGoogle Scholar
  31. 31.
    Tischendorf JJ, Meier PN, Schneider A et al (2007) Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 42: 1011–1017PubMedCrossRefGoogle Scholar
  32. 32.
    Tischendorf JJ, Kruger M, Trautwein C et al (2006) Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 38: 665–669PubMedCrossRefGoogle Scholar
  33. 33.
    Brentnall TA, Haggitt RC, Rabinovitch PS et al (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110: 331–338PubMedCrossRefGoogle Scholar
  34. 34.
    Kiesslich R, Fritsch J, Holtmann M et al (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124: 880–888PubMedCrossRefGoogle Scholar
  35. 35.
    Campbell WL, Ferris JV, Holbert BL et al (1998) Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US and MR imaging. Radiology 207: 41–50PubMedGoogle Scholar
  36. 36.
    Prytz H, Keiding S, Bjornsson E et al (2006) Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44: 1572–1580PubMedCrossRefGoogle Scholar
  37. 37.
    Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD (2008) Utility of serum tumor markers, imaging and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48: 1106–1117PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Klinik für Gastroenterologie, Hepatologie und EndokrinologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations